ARPC-MRI
Research type
Research Study
Full title
Adaptive radiotherapy for high-risk prostate cancer using multiparametric MRI (ARPC-MRI) - a feasibility study
IRAS ID
246092
Contact name
Angela L Turnbull
Contact email
Sponsor organisation
East and North Hertfordshire NHS Trust
Duration of Study in the UK
1 years, 7 months, 0 days
Research summary
Adaptive radiotherapy for high-risk prostate cancer using multiparametric MRI (ARPC-MRI) - a feasibility study
Mount Vernon Cancer Centre offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder or womb changes in bladder and womb size and position can be predicted allowing the creation of three radiotherapy treatment plans, each day the best fitting plan, i.e. the one that closely covers the tumour whilst giving minimal dose to normal tissues, is selected and used for treatment.
Small changes in shape and position of the prostate occur but cannot be predicted so adaptive radiotherapy based on physical change is not possible for prostate cancer treatments. However, recent research has shown that magnetic resonance imaging (MRI) can detect biological changes within the prostate in response to radiotherapy, some studies have seen changes as early as the second week of radiotherapy treatment. An observational study to investigate if these changes can support radiotherapy treatment plan adaption for prostate cancer treatments is proposed, whether the plan can be adapted to give a higher treatment dose to any areas of the prostate that show poor response to radiotherapy without increasing bowel and bladder dose is of particular interest. The treatment for patients who participate in the study would not be changed but the results may help to personalise and improve the treatment of future patients.
REC name
London - Hampstead Research Ethics Committee
REC reference
18/LO/1562
Date of REC Opinion
19 Oct 2018
REC opinion
Further Information Favourable Opinion